SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is drawing attention amid a steep selloff alongside other quantum-computing stocks, with traders citing high valuations, heavy losses and uncertainty over when the technology will generate meaningful commercial returns. Some see the decline as a buying opportunity, while others expect more downside and question whether upcoming results or company developments can reverse the trend.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a breakout to a fresh 52-week high, with traders positioning ahead of the Q3 report and watching BRIUMVI sales growth and guidance. Buyout and short-squeeze theories are also circulating, though some investors view the move as momentum ahead of earnings rather than evidence of a deal.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu shares are drawing attention after Lulas reelection triggered a sharp selloff across Brazilian stocks, with traders tying NUs decline to political and macroeconomic risk in its largest market rather than company-specific news. The community is split between viewing the move as an overreaction and buying opportunity, and expecting continued pressure from Brazil-related uncertainty.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas reported Baxfendy sales have prompted concern about the slow launch of aldosterone-synthase inhibitors and the commercial outlook for Mineralys lorundrostat, contributing to MLYSs sharp decline. Some traders view the early sales as a coverage-access ramp rather than a verdict on demand, while others question whether Mineralys can compete and launch successfully on its own; its FDA decision remains a key milestone.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is falling amid a broad semiconductor selloff after Intels weak forward guidance heightened concerns about PC demand and industry conditions. Traders point to the drop across chip peers, while some see the pullback as a buying opportunity ahead of Qualcomms earnings report.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta is drawing attention for heavy call-option activity, while traders debate whether bullish positioning can outweigh elevated jet-fuel costs and the reduced profit outlook. Strong travel demand and pricing power are seen as offsets, but the sustainability of margins remains uncertain.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in London, Canada.

Aduro Clean Technologies Inc

Attention centers on Aduros progress toward commercializing its Hydrochemolytic Technology, including pilot results on mixed polyolefin feedstocks and engineering work for its planned Chemelot facility; some investors also see paraffinic crude as a potential nearer-term application. Bullish holders view these as validation, while skeptics argue the company has yet to demonstrate viable economics or commercial-scale performance.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charters Q2 results have intensified debate over persistent broadband subscriber losses, competition and heavy debt, with concerns about weaker cash generation and paused buybacks weighing on sentiment. Bulls counter that the stocks low valuation, mobile growth and the Cox merger could support a recovery, while others remain skeptical about the deals added financing and dilution.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

Discussion is focused on onsemis emerging AI/data-center exposure: traders point to growth in the Other end-market category, which includes computing and data centers, but question how durable that demand is because long-term supply agreements can be changed or canceled. The debate is tempered by the companys continued exposure to automotive and industrial markets facing a cyclical slowdown, alongside the stocks recent weakness.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons Q3 results beat expectations, with strong refining performance and war-related fuel-market disruptions lifting downstream results; the company also highlighted shareholder returns. The reaction is broadly positive, though some traders question whether the refining boost will last and point to put-heavy options activity as a sign of downside caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026 /PRNewswire...

Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

Tyra Biosciences (TYRA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Oct. 8, 2026NEW YORK, Oct. 8, 2026 /PRNewswire...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Oct. 1, 2026NEW YORK, Oct. 1, 2026 /PRNewswire...

Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday

Nasdaq fell 1%, while Elmet surged 50.6% on $450M DoD funding plans; Rum, SailPoint, Tyra and cybersecurity stocks also rallied.read more...

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsPR NewswireCARLSBAD, Calif., Sept. 14, 2026 CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026 /PRNewswire...

Why Is Tyra Biosciences Stock Sinking Wednesday?

Tyra Biosciences stock fell sharply as initial dabogratinib Phase 2 data showed a 57% complete response rate at 60 mg.read more...

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib PR Newswire CARLSBAD...

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

Tyra Biosciences to Present at the Cantor Global Healthcare Conference Tyra Biosciences to Present at the Cantor Global Healthcare Conference PR Newswire CARLSBAD, Calif., Sept. 8, 2026 CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage...

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Tyra Biosciences Inc

TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The study is evaluating two once-daily doses of the drug, 50 mg and 60 mg.</li><li>The upcoming readout is expected to include safety results from more than 40 patients and efficacy results from more than 20 patients.</li><li>Tyra is also testing the drug for a rare type of urinary tract cancer.</li></ul>Tyra Biosciences (TYRA) was on investors’ radar after the biotech company said the initial clinical results from a key Phase 2 study of its experimental bladder cancer treatment will be announced next week.At the time of writing, <a href="https://stocktwits.com/symbol/TYRA">TYRA stock</a> was up more than 15% and is on track to clock its biggest single-day gains in nearly 10 months.Tyra said it will host a conference call and webcast on September 9 at 8 a.m. ET to discuss initial results from its SURF302 Phase 2 study evaluating oral Dabogratinib in patients with intermediate-risk non-muscle invasive bladder cancer.<h2 class="st-heading-2">SURF302 Study Details</h2>SURF302 is a multicenter, open-label Phase 2 study testing the efficacy and safety of Dabogratinib. The study is evaluating two once-daily doses of the drug, 50 mg and 60 mg. The upcoming readout is expected to include safety results from more than 40 patients and efficacy results from more than 20 patients across the two dose groups.<h2 class="st-heading-2">Cash Runway Extends Into 2028</h2>Tyra also has a sizable cash position as it advances its clinical pipeline. The company ended the second quarter with $353.9 million in cash, cash equivalents and marketable securities.Management expects its existing resources to fund operations into the second half of 2028 as Tyra advances Dabogratinib across multiple studies.Beyond SURF302, the company is testing the drug in SURF303, a Phase 2 study for a rare type of urinary tract cancer, with initial results expected in 2027. Tyra is also evaluating Dabogratinib in children with Achondroplasia, a genetic condition that affects bone growth, with initial data expected by the end of the first quarter of 2027.<h2 class="st-heading-2">Retail’s Take On TYRA</h2>Retail sentiment surrounding TYRA on Stocktwits improved to ‘bullish’ from ‘bearish’ a day earlier.One user said next week is going to be “very interesting”<stembedurl>https://stocktwits.com/Bone1977/message/663652755</stembedurl>The stock has gained more than 7% so far in 2026.Also read: August Jobs Data: <a href="https://stocktwits.com/news-articles/markets/equity/august-jobs-data-wolfe-s-chief-economist-says-hawkish-price-action-may-be-taking-the-print-a-little-too-far/cZsDXePRJDJ">Wolfe’s Chief Economist Says Hawkish Price Action May Be Taking The Print ‘A Little Too Far’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background. (Source: Getty Images)

 Tyra is set to host a conference call on September 9 to discuss initial results from its Phase 2 study evaluating Dabogratinib in patients with intermediate-risk non-muscle invasive bladder cancer.

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$21.07
Prev Close	$21.48
Open	$21.18
Dividend Yield	0.00%
50-Day Moving Average	$22.67
Beta	1.14
Avg. Volume	1.42M
PE Ratio	-8.81

52-Week High	$40.65
52-Week Low	$13.35
Market Capitalization	$1.45B
EPS (Annual)	-$2.01
Price to Book	3.55
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TYRA Fundamentals